Relief Therapeutics Holding AG (RLF.SW)

CHF 4.1

(-6.82%)

Long Term Debt Summary of Relief Therapeutics Holding AG

Relief Therapeutics Holding AG's latest annual long term debt in 2023 was 9000.00 CHF , down -43.75% from previous year.
Relief Therapeutics Holding AG's latest quarterly long term debt in 2024 Q2 was - CHF , down 0.0% from previous quarter.
Relief Therapeutics Holding AG reported annual long term debt of 16 Thousand CHF in 2022, down -95.96% from previous year.
Relief Therapeutics Holding AG reported annual long term debt of 396 Thousand CHF in 2021, down 0.0% from previous year.
Relief Therapeutics Holding AG reported quarterly long term debt of 9000.00 CHF for 2023 Q4, down 0.0% from previous quarter.
Relief Therapeutics Holding AG reported quarterly long term debt of 9000.00 CHF for 2023 FY, down -43.75% from previous quarter.

Annual Long Term Debt Chart of Relief Therapeutics Holding AG (2023 - 2007)

Historical Annual Long Term Debt of Relief Therapeutics Holding AG (2023 - 2007)

Year	Long Term Debt	Long Term Debt Growth
2023	9000.00 CHF	-43.75%
2022	16 Thousand CHF	-95.96%
2021	396 Thousand CHF	0.0%
2020	- CHF	0.0%
2019	- CHF	-100.0%
2018	4.31 Million CHF	0.0%
2017	- CHF	0.0%
2016	- CHF	-100.0%
2015	2.06 Million CHF	877.89%
2014	211.62 Thousand CHF	-93.45%
2013	3.23 Million CHF	3221.62%
2012	97.25 Thousand CHF	-23.56%
2011	127.22 Thousand CHF	-52.8%
2010	269.55 Thousand CHF	61.05%
2009	167.36 Thousand CHF	-49.17%
2008	329.25 Thousand CHF	-90.67%
2007	3.53 Million CHF	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q2	- CHF	0.0%
2023 Q4	9000.00 CHF	0.0%
2023 FY	9000.00 CHF	-43.75%
2023 Q2	13 Thousand CHF	0.0%
2022 FY	16 Thousand CHF	-95.96%
2022 Q4	16 Thousand CHF	0.0%
2022 Q2	385 Thousand CHF	0.0%
2021 FY	396 Thousand CHF	0.0%
2021 Q2	2.43 Million CHF	0.0%
2021 Q4	396 Thousand CHF	0.0%
2020 FY	- CHF	0.0%
2020 Q4	- CHF	0.0%
2020 Q2	- CHF	0.0%
2019 Q2	- CHF	0.0%
2019 FY	- CHF	-100.0%
2019 Q4	- CHF	0.0%
2018 Q4	4.31 Million CHF	0.0%
2018 Q2	4.36 Million CHF	0.0%
2018 FY	4.31 Million CHF	0.0%
2017 FY	- CHF	0.0%
2017 Q4	- CHF	0.0%
2017 Q2	- CHF	0.0%
2016 Q4	- CHF	0.0%
2016 Q2	- CHF	0.0%
2016 FY	- CHF	-100.0%
2015 Q4	2.06 Million CHF	0.0%
2015 Q2	2.14 Million CHF	0.0%
2015 FY	2.06 Million CHF	877.89%
2014 Q2	3.73 Million CHF	0.0%
2014 FY	211.62 Thousand CHF	-93.45%
2014 Q4	211.62 Thousand CHF	0.0%
2013 FY	3.23 Million CHF	3221.62%
2013 Q4	3.23 Million CHF	0.0%
2013 Q2	47.62 Thousand CHF	0.0%
2012 Q4	97.25 Thousand CHF	0.0%
2012 FY	97.25 Thousand CHF	-23.56%
2012 Q2	2.11 Million CHF	0.0%
2011 Q2	268.54 Thousand CHF	0.0%
2011 Q4	127.22 Thousand CHF	0.0%
2011 FY	127.22 Thousand CHF	-52.8%
2010 Q2	128.1 Thousand CHF	0.0%
2010 FY	269.55 Thousand CHF	61.05%
2010 Q4	269.55 Thousand CHF	0.0%
2009 Q4	167.36 Thousand CHF	0.0%
2009 FY	167.36 Thousand CHF	-49.17%
2009 Q2	286.21 Thousand CHF	0.0%
2008 FY	329.25 Thousand CHF	-90.67%
2008 Q4	329.25 Thousand CHF	0.0%
2007 FY	3.53 Million CHF	0.0%

Peer Long Term Debt Comparison of Relief Therapeutics Holding AG

Name	Long Term Debt	Long Term Debt Difference
Addex Therapeutics Ltd	70.38 Thousand CHF	87.212%
BB Biotech AG	304.9 Million CHF	99.997%
Basilea Pharmaceutica AG	95.45 Million CHF	99.991%
Evolva Holding SA	- CHF	-Infinity%
Idorsia Ltd	931 Million CHF	99.999%
Kuros Biosciences AG	1.56 Million CHF	99.425%
Molecular Partners AG	2.44 Million CHF	99.632%
Santhera Pharmaceuticals Holding AG	1.47 Million CHF	99.391%